Close Menu

NEW YORK (GenomeWeb) – Exact Sciences reported before the opening of the market on Wednesday that third quarter revenues increased 123 percent, due to a 100 percent uptick in the number of Cologuard colon cancer tests it completed during the quarter.

For the quarter ended Sept. 30, the molecular diagnostics company reported revenues of $28.1 million, up from $12.6 million in the year-ago quarter, and beating the average Wall Street analyst estimate for revenues of $25.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.